Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2003 Jan;95(1):30–42.

An update on 'progression promoters' in renal diseases.

C O Alebiosu 1
PMCID: PMC2594375  PMID: 12656448

Abstract

AIM: This paper reviews progression in renal diseases. METHODS: An English language literature search using Medline (1980 January-2001 July) was done to assess research and review articles on progression in renal diseases. RESULTS: Factors that increase the risk of progression in renal diseases are hypertension, dyslipidaemia, underlying nephropathy, high dietary protein intake and proteinuria. Others are smoking, hyperglycemia, low birth weight, obesity, metabolic syndrome X, genetic factors such as angiotensin converting enzyme 'DD' genotype and chromosome 1q21, and exposure to lead. Hypertension induces arteriolar nephrosclerosis. The mechanisms whereby lipids contribute to vascular and renal injury are incompletely understood. Glomerular hyperperfusion and increased proteinuria may explain the adverse effects of increased protein intake on renal disease progression. Proteinuria contains numerous toxic/inflammatory systems that promote progression. Cigarette smoking has vasoconstrictive, thrombotic and direct toxic effects on the vascular epithelium. Hyperglycemia is strongly implicated in the progression of complications in diabetics. Oligonephropathy in low birth weight has been suggested to increase the risk for systemic and glomerular hypertension in adult life. In obesity, the combination of hyperfiltration, glomerular hypertrophy and glomerular hypertension is a primary initiating event for glomerular injury manifesting as glomerulomegally and focal and segmental glomerulosclerosis and proteinuria. Angiotensin I, with enzyme insertion/deletion polymorphism, especially the "DD" genotype, predisposes to a rapid decline in renal function. Finally, long-term exposure to low levels of environmental lead affects renal function. CONCLUSION: The control of hypertension, dyslipidaemia, proteinuria, obesity, avoidance of low birth weight, smoking and heavy metals such as lead are intervention strategies for preventing progression of renal diseases.

Full text

PDF
30

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baggio B., Budakovic A., Gambaro G. Cardiovascular risk factors, smoking and kidney function. Nephrol Dial Transplant. 1998;13 (Suppl 7):2–5. doi: 10.1093/ndt/13.suppl_7.2. [DOI] [PubMed] [Google Scholar]
  2. Barker D. J., Bull A. R., Osmond C., Simmonds S. J. Fetal and placental size and risk of hypertension in adult life. BMJ. 1990 Aug 4;301(6746):259–262. doi: 10.1136/bmj.301.6746.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brenner B. M., Meyer T. W., Hostetter T. H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982 Sep 9;307(11):652–659. doi: 10.1056/NEJM198209093071104. [DOI] [PubMed] [Google Scholar]
  4. Chapman A. B., Johnson A. M., Gabow P. A., Schrier R. W. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994 Dec;5(6):1349–1354. doi: 10.1681/ASN.V561349. [DOI] [PubMed] [Google Scholar]
  5. Coggins C. H., Breyer Lewis J., Caggiula A. W., Castaldo L. S., Klahr S., Wang S. R. Differences between women and men with chronic renal disease. Nephrol Dial Transplant. 1998 Jun;13(6):1430–1437. doi: 10.1093/ndt/13.6.1430. [DOI] [PubMed] [Google Scholar]
  6. Cohn D. H., Shohat T., Yahav M., Ilan T., Rechavi G., King L., Shohat M. A locus for an autosomal dominant form of progressive renal failure and hypertension at chromosome 1q21. Am J Hum Genet. 2000 Aug 4;67(3):647–651. doi: 10.1086/303051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Converse R. L., Jr, Jacobsen T. N., Toto R. D., Jost C. M., Cosentino F., Fouad-Tarazi F., Victor R. G. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992 Dec 31;327(27):1912–1918. doi: 10.1056/NEJM199212313272704. [DOI] [PubMed] [Google Scholar]
  8. De Jong P. E., Navis G., de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet. 1999 Jul 31;354(9176):352–353. doi: 10.1016/S0140-6736(99)90122-8. [DOI] [PubMed] [Google Scholar]
  9. Dickinson J. P., Prentice C. R. Aspirin: benefit and risk in thromboprophylaxis. QJM. 1998 Aug;91(8):523–538. doi: 10.1093/qjmed/91.8.523. [DOI] [PubMed] [Google Scholar]
  10. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl. 2000 Sep;77:S3–12. doi: 10.1046/j.1523-1755.2000.07702.x. [DOI] [PubMed] [Google Scholar]
  11. Flegal K. M., Carroll M. D., Kuczmarski R. J., Johnson C. L. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998 Jan;22(1):39–47. doi: 10.1038/sj.ijo.0800541. [DOI] [PubMed] [Google Scholar]
  12. Fried L. F., Orchard T. J., Kasiske B. L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001 Jan;59(1):260–269. doi: 10.1046/j.1523-1755.2001.00487.x. [DOI] [PubMed] [Google Scholar]
  13. Gambaro G., Verlato F., Budakovic A., Casara D., Saladini G., Del Prete D., Bertaglia G., Masiero M., Checchetto S., Baggio B. Renal impairment in chronic cigarette smokers. J Am Soc Nephrol. 1998 Apr;9(4):562–567. doi: 10.1681/ASN.V94562. [DOI] [PubMed] [Google Scholar]
  14. Gilbert R. E., Cooper M. E. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. 1999 Nov;56(5):1627–1637. doi: 10.1046/j.1523-1755.1999.00721.x. [DOI] [PubMed] [Google Scholar]
  15. Goetz F. C., Jacobs D. R., Jr, Chavers B., Roel J., Yelle M., Sprafka J. M. Risk factors for kidney damage in the adult population of Wadena, Minnesota. A prospective study. Am J Epidemiol. 1997 Jan 15;145(2):91–102. doi: 10.1093/oxfordjournals.aje.a009091. [DOI] [PubMed] [Google Scholar]
  16. Halimi J. M., Giraudeau B., Vol S., Cacès E., Nivet H., Lebranchu Y., Tichet J. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int. 2000 Sep;58(3):1285–1292. doi: 10.1046/j.1523-1755.2000.00284.x. [DOI] [PubMed] [Google Scholar]
  17. He J., Whelton P. K., Vu B., Klag M. J. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998 Dec 9;280(22):1930–1935. doi: 10.1001/jama.280.22.1930. [DOI] [PubMed] [Google Scholar]
  18. Hebert L. A., Bain R. P., Verme D., Cattran D., Whittier F. C., Tolchin N., Rohde R. D., Lewis E. J. Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int. 1994 Dec;46(6):1688–1693. doi: 10.1038/ki.1994.469. [DOI] [PubMed] [Google Scholar]
  19. Hebert L. A., Kusek J. W., Greene T., Agodoa L. Y., Jones C. A., Levey A. S., Breyer J. A., Faubert P., Rolin H. A., Wang S. R. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension. 1997 Sep;30(3 Pt 1):428–435. doi: 10.1161/01.hyp.30.3.428. [DOI] [PubMed] [Google Scholar]
  20. Hebert L. A., Wilmer W. A., Falkenhain M. E., Ladson-Wofford S. E., Nahman N. S., Jr, Rovin B. H. Renoprotection: one or many therapies? Kidney Int. 2001 Apr;59(4):1211–1226. doi: 10.1046/j.1523-1755.2001.0590041211.x. [DOI] [PubMed] [Google Scholar]
  21. Hostetter T. H., Olson J. L., Rennke H. G., Venkatachalam M. A., Brenner B. M. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol. 1981 Jul;241(1):F85–F93. doi: 10.1152/ajprenal.1981.241.1.F85. [DOI] [PubMed] [Google Scholar]
  22. Hovind P., Rossing P., Tarnow L., Smidt U. M., Parving H. H. Progression of diabetic nephropathy. Kidney Int. 2001 Feb;59(2):702–709. doi: 10.1046/j.1523-1755.2001.059002702.x. [DOI] [PubMed] [Google Scholar]
  23. Hunsicker L. G., Adler S., Caggiula A., England B. K., Greene T., Kusek J. W., Rogers N. L., Teschan P. E. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997 Jun;51(6):1908–1919. doi: 10.1038/ki.1997.260. [DOI] [PubMed] [Google Scholar]
  24. Inzucchi S. E., Maggs D. G., Spollett G. R., Page S. L., Rife F. S., Walton V., Shulman G. I. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998 Mar 26;338(13):867–872. doi: 10.1056/NEJM199803263381303. [DOI] [PubMed] [Google Scholar]
  25. Joles J. A., Kunter U., Janssen U., Kriz W., Rabelink T. J., Koomans H. A., Floege J. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol. 2000 Apr;11(4):669–683. doi: 10.1681/ASN.V114669. [DOI] [PubMed] [Google Scholar]
  26. Jovanovic D. B., Djukanovic L. Analysis of factors influencing chronic renal failure progression. Ren Fail. 1999 Mar;21(2):177–187. doi: 10.3109/08860229909066982. [DOI] [PubMed] [Google Scholar]
  27. Jungers P., Hannedouche T., Itakura Y., Albouze G., Descamps-Latscha B., Man N. K. Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors. Nephrol Dial Transplant. 1995;10(8):1353–1360. [PubMed] [Google Scholar]
  28. Kambham N., Markowitz G. S., Valeri A. M., Lin J., D'Agati V. D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001 Apr;59(4):1498–1509. doi: 10.1046/j.1523-1755.2001.0590041498.x. [DOI] [PubMed] [Google Scholar]
  29. Kambham N., Markowitz G. S., Valeri A. M., Lin J., D'Agati V. D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001 Apr;59(4):1498–1509. doi: 10.1046/j.1523-1755.2001.0590041498.x. [DOI] [PubMed] [Google Scholar]
  30. Kasiske B. L., O'Donnell M. P., Cleary M. P., Keane W. F. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1988 Mar;33(3):667–672. doi: 10.1038/ki.1988.51. [DOI] [PubMed] [Google Scholar]
  31. Kasiske B. L., O'Donnell M. P., Garvis W. J., Keane W. F. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res. 1988 Feb;62(2):367–374. doi: 10.1161/01.res.62.2.367. [DOI] [PubMed] [Google Scholar]
  32. Keane W. F. Lipids and the kidney. Kidney Int. 1994 Sep;46(3):910–920. doi: 10.1038/ki.1994.349. [DOI] [PubMed] [Google Scholar]
  33. Keane W. F., O'Donnell M. P., Kasiske B. L., Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol. 1993 Aug;4(2):187–194. doi: 10.1681/ASN.V42187. [DOI] [PubMed] [Google Scholar]
  34. Klag M. J., Whelton P. K., Randall B. L., Neaton J. D., Brancati F. L., Ford C. E., Shulman N. B., Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996 Jan 4;334(1):13–18. doi: 10.1056/NEJM199601043340103. [DOI] [PubMed] [Google Scholar]
  35. Klahr S., Schreiner G., Ichikawa I. The progression of renal disease. N Engl J Med. 1988 Jun 23;318(25):1657–1666. doi: 10.1056/NEJM198806233182505. [DOI] [PubMed] [Google Scholar]
  36. Kuriyama S., Tomonari H., Yoshida H., Hashimoto T., Kawaguchi Y., Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77(2):176–185. doi: 10.1159/000190270. [DOI] [PubMed] [Google Scholar]
  37. Levey A. S., Greene T., Beck G. J., Caggiula A. W., Kusek J. W., Hunsicker L. G., Klahr S. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol. 1999 Nov;10(11):2426–2439. doi: 10.1681/ASN.V10112426. [DOI] [PubMed] [Google Scholar]
  38. Lin J. L., Ho H. H., Yu C. C. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial. Ann Intern Med. 1999 Jan 5;130(1):7–13. doi: 10.7326/0003-4819-130-1-199901050-00003. [DOI] [PubMed] [Google Scholar]
  39. Locatelli F., Alberti D., Graziani G., Buccianti G., Redaelli B., Giangrande A. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet. 1991 Jun 1;337(8753):1299–1304. doi: 10.1016/0140-6736(91)92977-a. [DOI] [PubMed] [Google Scholar]
  40. Maddox David A., Alavi Fred K., Silbernick Elizabeth M., Zawada Edward T. Protective effects of a soy diet in preventing obesity-linked renal disease. Kidney Int. 2002 Jan;61(1):96–104. doi: 10.1046/j.1523-1755.2002.00091.x. [DOI] [PubMed] [Google Scholar]
  41. Maroni B. J., Mitch W. E. Role of nutrition in prevention of the progression of renal disease. Annu Rev Nutr. 1997;17:435–455. doi: 10.1146/annurev.nutr.17.1.435. [DOI] [PubMed] [Google Scholar]
  42. Maschio G., Alberti D., Janin G., Locatelli F., Mann J. F., Motolese M., Ponticelli C., Ritz E., Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996 Apr 11;334(15):939–945. doi: 10.1056/NEJM199604113341502. [DOI] [PubMed] [Google Scholar]
  43. Moorhead J. F., Chan M. K., El-Nahas M., Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982 Dec 11;2(8311):1309–1311. doi: 10.1016/s0140-6736(82)91513-6. [DOI] [PubMed] [Google Scholar]
  44. Mänttäri M., Tiula E., Alikoski T., Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995 Oct;26(4):670–675. doi: 10.1161/01.hyp.26.4.670. [DOI] [PubMed] [Google Scholar]
  45. Nair K. S., Pabico R. C., Truglia J. A., McKenna B. A., Statt M., Lockwood D. H. Mechanism of glomerular hyperfiltration after a protein meal in humans. Role of hormones and amino acids. Diabetes Care. 1994 Jul;17(7):711–715. doi: 10.2337/diacare.17.7.711. [DOI] [PubMed] [Google Scholar]
  46. Nishikawa T., Edelstein D., Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl. 2000 Sep;77:S26–S30. doi: 10.1046/j.1523-1755.2000.07705.x. [DOI] [PubMed] [Google Scholar]
  47. Nomura A., Morita Y., Maruyama S., Hotta N., Nadai M., Wang L., Hasegawa T., Matsuo S. Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol. 1997 Aug;151(2):539–547. [PMC free article] [PubMed] [Google Scholar]
  48. Oda H., Keane W. F. Recent advances in statins and the kidney. Kidney Int Suppl. 1999 Jul;71:S2–S5. doi: 10.1046/j.1523-1755.1999.07101.x. [DOI] [PubMed] [Google Scholar]
  49. Ogrodowski J. L., Hebert L. A., Sedmak D., Cosio F. G., Tamerius J., Kolb W. Measurement of SC5b-9 in urine in patients with the nephrotic syndrome. Kidney Int. 1991 Dec;40(6):1141–1147. doi: 10.1038/ki.1991.326. [DOI] [PubMed] [Google Scholar]
  50. Olivarius N. de F., Andreasen A. H., Keiding N., Mogensen C. E. Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study "Diabetes Care in General Practice", Denmark. Diabetologia. 1993 Oct;36(10):1007–1016. doi: 10.1007/BF02374492. [DOI] [PubMed] [Google Scholar]
  51. Orth S. R., Ritz E., Schrier R. W. The renal risks of smoking. Kidney Int. 1997 Jun;51(6):1669–1677. doi: 10.1038/ki.1997.232. [DOI] [PubMed] [Google Scholar]
  52. Pavlovic M., Reile M., Haeberle U., Schwarz K., Heinze E., Teller W., Lang D., Holl R. W. Angiotensin I-converting enzyme-gene-polymorphism: relationship to albumin excretion and blood pressure in pediatric patients with type-I-diabetes mellitus. Exp Clin Endocrinol Diabetes. 1997;105(5):248–253. doi: 10.1055/s-0029-1211761. [DOI] [PubMed] [Google Scholar]
  53. Reaven G. M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988 Dec;37(12):1595–1607. doi: 10.2337/diab.37.12.1595. [DOI] [PubMed] [Google Scholar]
  54. Reed T. On the association between adult blood pressure and dermatoglyphics as prenatal markers of development. J Hypertens. 1995 Jun;13(6):595–601. doi: 10.1097/00004872-199506000-00004. [DOI] [PubMed] [Google Scholar]
  55. Refsum H., Ueland P. M., Nygård O., Vollset S. E. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31–62. doi: 10.1146/annurev.med.49.1.31. [DOI] [PubMed] [Google Scholar]
  56. Remuzzi G., Ruggenenti P., Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997 Jan;51(1):2–15. doi: 10.1038/ki.1997.2. [DOI] [PubMed] [Google Scholar]
  57. Riser B. L., Cortes P., Zhao X., Bernstein J., Dumler F., Narins R. G. Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest. 1992 Nov;90(5):1932–1943. doi: 10.1172/JCI116071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Ritz E., Schömig M., Wagner J. Counteracting progression of renal disease: A look into the future. Kidney Int Suppl. 2000 Apr;75:S71–S76. doi: 10.1046/j.1523-1755.2000.07513.x. [DOI] [PubMed] [Google Scholar]
  59. Ritz E., Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis. 1996 Feb;27(2):167–194. doi: 10.1016/s0272-6386(96)90538-7. [DOI] [PubMed] [Google Scholar]
  60. Rosenberg M. E., Chmielewski D., Hostetter T. H. Effect of dietary protein on rat renin and angiotensinogen gene expression. J Clin Invest. 1990 Apr;85(4):1144–1149. doi: 10.1172/JCI114546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Rossing P., Tarnow L., Nielsen F. S., Hansen B. V., Brenner B. M., Parving H. H. Low birth weight. A risk factor for development of diabetic nephropathy? Diabetes. 1995 Dec;44(12):1405–1407. doi: 10.2337/diab.44.12.1405. [DOI] [PubMed] [Google Scholar]
  62. Rovin B. H., Doe N., Tan L. C. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis. 1996 May;27(5):640–646. doi: 10.1016/s0272-6386(96)90097-9. [DOI] [PubMed] [Google Scholar]
  63. Samuelsson O., Attman P. O., Knight-Gibson C., Larsson R., Mulec H., Weiss L., Alaupovic P. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol. 1998 Aug;9(8):1482–1488. doi: 10.1681/ASN.V981482. [DOI] [PubMed] [Google Scholar]
  64. Samuelsson O., Aurell M., Knight-Gibson C., Alaupovic P., Attman P. O. Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron. 1993;63(3):279–285. doi: 10.1159/000187210. [DOI] [PubMed] [Google Scholar]
  65. Samuelsson O., Mulec H., Knight-Gibson C., Attman P. O., Kron B., Larsson R., Weiss L., Wedel H., Alaupovic P. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997 Sep;12(9):1908–1915. doi: 10.1093/ndt/12.9.1908. [DOI] [PubMed] [Google Scholar]
  66. Schalekamp M. A., Schalekamp-Kuyken M. P., de Moor-Fruytier M., Meininger T., Vaandrager-Kranenburg D. J., Birkenhäger W. H. Interrelationships between blood pressure, renin, renin substrate and blood volume in terminal renal failure. Clin Sci Mol Med. 1973 Oct;45(4):417–428. doi: 10.1042/cs0450417. [DOI] [PubMed] [Google Scholar]
  67. Silbiger S. R., Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis. 1995 Apr;25(4):515–533. doi: 10.1016/0272-6386(95)90119-1. [DOI] [PubMed] [Google Scholar]
  68. Stenvinkel P., Alvestrand A., Bergström J. Factors influencing progression in patients with chronic renal failure. J Intern Med. 1989 Sep;226(3):183–188. doi: 10.1111/j.1365-2796.1989.tb01377.x. [DOI] [PubMed] [Google Scholar]
  69. Taal M. W., Brenner B. M. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000 May;57(5):1803–1817. doi: 10.1046/j.1523-1755.2000.00031.x. [DOI] [PubMed] [Google Scholar]
  70. Touam M., Zingraff J., Jungers P., Chadefaux-Vekemans B., Drüeke T., Massy Z. A. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int. 1999 Dec;56(6):2292–2296. doi: 10.1046/j.1523-1755.1999.00792.x. [DOI] [PubMed] [Google Scholar]
  71. Viswanathan V., Zhu Y., Bala K., Dunn S., Snehalatha C., Ramachandran A., Jayaraman M., Sharma K. Association between ACE gene polymorphism and diabetic nephropathy in South Indian patients. JOP. 2001 Mar;2(2):83–87. [PubMed] [Google Scholar]
  72. Walser M., Mitch W. E., Maroni B. J., Kopple J. D. Should protein intake be restricted in predialysis patients? Kidney Int. 1999 Mar;55(3):771–777. doi: 10.1046/j.1523-1755.1999.055003771.x. [DOI] [PubMed] [Google Scholar]
  73. Wapstra F. H., Navis G., de Jong P. E., de Zeeuw D. Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Exp Nephrol. 1996;4 (Suppl 1):47–52. [PubMed] [Google Scholar]
  74. Washio M., Okuda S., Ikeda M., Hirakata H., Nanishi F., Onoyama K., Yoshimura T., Fujishima M. Hypercholesterolemia and the progression of the renal dysfunction in chronic renal failure patients. J Epidemiol. 1996 Dec;6(4):172–177. doi: 10.2188/jea.6.172. [DOI] [PubMed] [Google Scholar]
  75. Weder A. B., Schork N. J. Adaptation, allometry, and hypertension. Hypertension. 1994 Aug;24(2):145–156. doi: 10.1161/01.hyp.24.2.145. [DOI] [PubMed] [Google Scholar]
  76. Weisinger J. R., Kempson R. L., Eldridge F. L., Swenson R. S. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med. 1974 Oct;81(4):440–447. doi: 10.7326/0003-4819-81-4-440. [DOI] [PubMed] [Google Scholar]
  77. Wheeler D. C., Bernard D. B. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis. 1994 Mar;23(3):331–346. doi: 10.1016/s0272-6386(12)80994-2. [DOI] [PubMed] [Google Scholar]
  78. Yang W. Q., Song N. G., Ying S. S., Liang H. Q., Zhang Y. J., Wei M. J., Wu K. F. Serum lipid concentrations correlate with the progression of chronic renal failure. Clin Lab Sci. 1999 Mar-Apr;12(2):104–108. [PubMed] [Google Scholar]
  79. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):145–153. doi: 10.1056/NEJM200001203420301. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES